Driven by the expansion in therapeutic applications, the intranasal drug delivery market in the United States, is projected to reach US$ 2.6 billion by the year 2010. As the market for intranasal drugs for local infections and chronic allergies matures, other emerging therapeutic areas are expected to strengthen their foothold in the marketplace.
San Jose, California (PRWEB) July 12, 2007 -- Intranasal Drug Delivery market, in the United States, is witnessing an expansion of therapeutic applications from the delivery of conventional local therapeutic drugs to the delivery of systemic therapeutic drugs. The future of the technology hinges onto to the effective exploitation of the fact that the nose offers an en-route that bypasses the blood-brain barrier through the olfactory region. Development of CNS drugs for nasal delivery will help the market score huge gains in the upcoming years.
The market also stands enthused by the continuous research and development activities, which are gradually opening up opportunities in new therapeutic areas, such as, osteoporosis, pain management, vitamin B12 deficiency, smoking cessation, migraines, nocturnal enuresis, rheumatoid arthritis, sexual dysfunction, cancer therapy, insulin-dependent diabetes, and epilepsy. The biggest growth traction in the intranasal drug delivery market is expected to stem from the development of new nasal drugs for treating sexual dysfunction. Yet to emerge from the sphere of research and development, drug development in this category shows promising signs of commercial success and marketability. Intranasal sexual dysfunction drugs market by the year 2012 is projected to reach a value of US$ 487 million in the United States.
Innovation in nasal drug delivery devices & equipments, like Preservative Free Systems (P.F.S.), is expected to help intranasal drug delivery inch closer towards widespread acceptance in the medical community. P.F.S additionally help realize the elusive goal of developing non-preserved drug formulations. Innovative and cutting edge delivery techniques like Bi-Directional nasal drug delivery offer a pragmatic solution to the conventional drawback and pitfall of drugs being inhaled into the lungs, which incidentally has been the major stumbling block for intranasal drug delivery. Advancements in nasal drug formulation, especially in the sphere of developing therapeutic proteins and peptides, is helping provide greater therapeutic benefits in the form of superior bioadhesion, and bioavailability, greater drug permeation, and absorption. All of the discussed trends are few of the market drivers, which are expected to provide the impetus required to push the intranasal drug delivery market out of its orbit.
Intranasal Allergic Infections Drugs market, as a therapeutic segment, is the largest revenue generator accounting for a share of 83.6% in the total market. Intranasal Analgesics Drugs market is forecasted to record the highest CAGR of 10.8% over the study's review period. Intranasal Osteoporosis drugs market, flaunts the potential to rise by over US$ 320.67 million between the period 2007 to 2010. Intranasal Vaccinations market, which presently constitutes less than 2% of the market, is projected to corner over 5.8% of the market by the year 2010.
Dominant players operating in the industry include Aegis Therapeutics LLC, AstraZeneca Plc, Alza Corporation, AptarGroup, Inc., Archimedes Pharma, Bayer Consumer Care, Bespak Plc, GlaxoSmithKline Plc, Intranasal Therapeutics, Inc., Javelin Pharmaceuticals, Inc, Kurve Technology, Inc., MedImmune, Inc., Nastech Pharmaceutical Company, Inc., OptiNose AS, Novartis AG, Pfizer, Inc., Sanofi-Aventis S.A. and Schering-Plough Corporation, among others.
The report titled "Intranasal Drug Delivery: A US Market Report" provides a comprehensive review of technology trends, market drivers, issues, challenges, and competition prevalent in the United States. Richly annotated with authoritative, and unbiased commentaries, and hard-to-find statistical facts, the report provides unequivocal views on future potential while throwing light on the prevailing climate in key product markets. Latent demand patterns in the United States are quantified across major therapeutic areas, which include Allergic Infections, Analgesics, Osteoporosis, and Vaccinations. Also provided in the report is an enumeration of recent mergers, acquisitions, and other strategic industry activities.
For more details about this research report, please visit www.strategyr.com/MCP-1795.asp.
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Web Site www.StrategyR.com
###
Trackback URL: http://www.prweb.com/pingpr.php/VGhpci1JbnNlLVBpZ2ctUGlnZy1UaGlyLVplcm8=
|
